tyrphostin ag957 and imatinib mesylate

tyrphostin ag957 has been researched along with imatinib mesylate in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Elefanty, A; Layton, JE; Lieschke, GJ; Sun, X	1
Dann, EJ; Eytan, GD; Regev, R; Yeheskely-Hayon, D	1

Other Studies

2 other study(ies) available for tyrphostin ag957 and imatinib mesylate

Article	Year
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571. Blood, 2001, Apr-01, Volume: 97, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; DNA Damage; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; K562 Cells; Leukemia; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Recombinant Fusion Proteins; Signal Transduction; Transfection; Tumor Cells, Cultured; Tyrphostins	2001
The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line. Leukemia research, 2005, Volume: 29, Issue:7 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biological Transport; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tyrphostins	2005

Article

Year

Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

Blood, 2001, Apr-01, Volume: 97, Issue:7

Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; DNA Damage; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; K562 Cells; Leukemia; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Recombinant Fusion Proteins; Signal Transduction; Transfection; Tumor Cells, Cultured; Tyrphostins

2001

The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line.

Leukemia research, 2005, Volume: 29, Issue:7

Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biological Transport; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tyrphostins

2005